SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

REGENXBIO Reports Third-Quarter 2026 Results

REGENXBIO reported third-quarter 2026 financial results and operational highlights. Its RGX-202 BLA submission for Duchenne muscular dystrophy is on track for Q1 2027, with potential acceleration.

RGNX
SquawkNews Desk 1 updates Updated Nov 05, 2026, 12:05 PM UTC

Story updates

12:05:58 PM UTC
SquawkNews
ROCKVILLE, Md., Nov. 5, 2026 // -- REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the third quarter ended September 30, 2026."We are continuing to build momentum as we prepare to launch potential first- or best-in-class gene therapies in 2027…

Related stories

Papa John's Reports Q3 EPS In Line, Revenue Misses Papa John's reported Q3 earnings of $0.16 per share, excluding non-recurring items, in line with FactSet estimates. Revenue missed estimates. M impact | EQUITY | Nov 05, 2026, 12:14 PM UTC Marex Group reports Q3 earnings of $1.67 per share Marex Group reported Q3 earnings of $1.67 per share, excluding non-recurring items, $0.13 above expectations. The headline also says revenue beat expectations. M impact | EQUITY | Nov 05, 2026, 12:13 PM UTC Wendy’s Q3 Adjusted EPS Tops Estimate, Revenue Falls Short Wendy’s reported adjusted EPS of USD 0.13 versus an IBES estimate of USD 0.09. Q3 adjusted revenue was USD 435.6 million versus an IBES estimate of USD 530.5 million. M impact | EQUITY | Nov 05, 2026, 12:09 PM UTC DNOW Q3 Profit Beats Estimates on Growth Across Segments M impact | EQUITY | Nov 05, 2026, 12:09 PM UTC Malibu Boats reports Q1 net loss Malibu Boats reported Q1 net income of USD -6.1 million; Reuters also reported gross profit of USD 37.8 million. M impact | EQUITY | Nov 05, 2026, 12:09 PM UTC Amylyx Pharmaceuticals Reports $45.5M Third-Quarter Loss M impact | EQUITY | Nov 05, 2026, 12:09 PM UTC